Galderma has announced the U.S. launch of its “Twyneo” Cream, 0.1%/3% at the American Academy of Dermatology (AAD) Annual Meeting, March 25-29, 2022, in Boston, Massachusetts.

Twyneo Cream is the first and only 0.1% tretinoin and 3% benzoyl peroxide (BPO) 2-in-1 combination proven to rapidly treat moderate to severe facial acne. Patented microencapsulation technology unites two ingredients that have not been previously combined and enables their controlled release to deliver visible results in as little as two weeks.

“Effective prescription acne treatments currently involve multi-step regimens because there is rarely a single treatment option that addresses the multiple causes of the skin condition. These routines can often result in low adherence, especially among boys,” said Caroline Robinson, MD, FAAD, Founder of Tone Dermatology.

“Twyneo Cream may help teens with acne – especially the boys –struggling with generic tretinoin or adhering to complex treatment routines, since it’s a once-daily, potent combination that can be used any time of day.”

In clinical trials, some people saw results in as little as two weeks of using TWYNEO Cream, and their skin continued to clear over time. These studies demonstrated a 25 percent decrease in pimples at two weeks and a 58–66 percent decrease at 12 weeks.

“Twyneo Cream is a novel and exciting medical advance because its microencapsulation technology enables the combination of BPO with the highest concentration of tretinoin available. While these two treatments can be difficult to tolerate in high concentrations, Twyneo Cream was well tolerated,” said Hillary Baldwin, MD, Medical Director of Acne Treatment & Research Center and principal investigator for the clinical trials.

She continues, “The patented microencapsulation technology in TWYNEO Cream segregates and envelopes the active ingredients in silica core shells that keep both crystals separate and stable while gradually releasing onto the skin.”

It is available throughout the U.S. by prescription.